Aim: This study compared the efficacy and safety of aripiprazole/sertraline combination (ASC) and placebo/sertraline combination (PSC) in patients with major depressive disorder (MDD) who showed an inadequate response to sertraline 100 mg/day.
I
N CLINICAL PRACTICE, approximately 30-50% of patients with major depressive disorder (MDD) do not achieve remission to standard antidepressant therapy (ADT).
1,2 Augmentation of ADT with an atypical antipsychotic agent is a treatment option for patients who do not obtain sufficient benefit from an adequate course of ADT. [3] [4] [5] Aripiprazole is pharmacologically distinct from other antipsychotics, acting as a partial agonist at the dopamine D 2 , D 3 , and serotonin 5-HT 1A receptors and as an antagonist at the 5-HT 2A receptors. 6, 7 It is approved for use as an adjunctive treatment to ADT in adults with MDD on the basis of results from large, multicenter, randomized, double-blind, placebo-controlled studies in the USA and Japan. [8] [9] [10] [11] These studies demonstrated the efficacy of adjunctive aripiprazole in patients with an inadequate response to a prospective 8-week treatment of the same ADT and at least one historical ADT treatment. [8] [9] [10] [11] Sertraline was launched in Japan in 2006 and is currently one of the top three antidepressants prescribed in Japan, according to a 2013 survey. 12 In the 2013 Research in East Asian Psychotropic Prescription Patterns on Antidepressants (REAP-AD) study, the top five antidepressants (in terms of percentage of antidepressant prescriptions) were fluoxetine (16%), sertraline (15%), escitalopram (14%), mirtazapine (10%), and paroxetine (8%). 12 Sertraline is one of the most widely used antidepressants in Japan and East Asia.
In a previous study of aripiprazole augmentation to ADT in Japan, at the time of randomization to double-blind treatment, the overall distribution of ADT was as follows: sertraline, 38.4%; fluvoxamine, 20.0%; paroxetine, 19.3%; milnacipran, 12.8%; and duloxetine, 9.6%. 11 According to the results of posthoc analyses of that study, patients who received sertraline and adjunctive aripiprazole flexible dose (3-15 mg/day) or aripiprazole fixed dose (3 mg/ day) experienced greater improvement in their mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score (−10.7 and −11.3, respectively) at study end-point than patients treated with adjunctive placebo (MADRS total score, −6.4). 13 This posthoc result suggests that aripiprazole/sertraline combination (ASC) may be effective for patients with an inadequate response to sertraline 100 mg/day. However, this has not been demonstrated in a clinical study.
The aim of the present study was to compare the efficacy, safety, and tolerability of ASC versus placebo/sertraline combination (PSC) in MDD patients with an inadequate response to sertraline treatment.
METHODS
This multicenter, randomized, double-blind, placebo-controlled study was conducted at 134 sites in Japan, Korea, Malaysia, Taiwan, and Australia between February 2014 and September 2016, in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice Consolidated and the applicable local laws and regulatory requirements of the countries in which the study was conducted. The protocol was approved by the institutional review board of Medical Corporation Jisenkai Nankokokorono Clinic and conformed to the provisions of the Declaration of Helsinki. All patients (or their guardian or legal representative, as applicable according to local laws) provided written informed consent to participate in the study. The study is registered at ClinicalTrials. gov (identifier: NCT02046564).
Patients
Patients who were eligible for enrollment in the screening period were required to be aged 20-65 years and to meet the DSM-5 14 criteria for MDD as a primary diagnosis, with a score of ≥18 on the 17-item Hamilton Depression Rating Scale (HAM-D17). 15 Patients were also required to have had a major depressive episode that had lasted ≥8 weeks, and to show inadequate response to one to three courses of adequate ADT for their current episodes of MDD.
Patients were excluded if they had a diagnosis of any of the following disorders as defined by the DSM-5: neurocognitive disorders, schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, feeding and eating disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, substance use disorders, or a personality disorder (borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic). Patients experiencing hallucinations, delusions, or moodincongruent psychotic symptoms in the current depressive episode were also excluded, as were those with an item suicide score on HAM-D17 of ≥3 and a suicidal risk. In addition, patients were excluded if they: had received electroconvulsive therapy; had a history of neuroleptic malignant syndrome, serotonin syndrome, or seizure disorder; had a history of treatment with aripiprazole in their current episode of major depression; had enrolled in a clinical study of aripiprazole; had enrolled in a clinical study with another investigational product within 1 month at the time of informed consent; required new hospitalization in the current episode during the screening period; were taking an adjunctive antipsychotic (except sulpiride used for the treatment of depression, depressive states, or gastroduodenal ulcers) or psychostimulant drug during the current episode; and had received treatment with a monoamine oxidase inhibitor within 2 weeks prior to the prospective treatment (single-blind sertraline 25-100 mg/day) period and with benzodiazepines (except for ultra-short-acting sleep-inducing benzodiazepines) within 1 week prior to the prospective treatment period.
Study design
This study consisted of a screening period, a prospective treatment period, a double-blind treatment period (or single-blind sertraline extension period for sertraline responders), a sertraline-tapering period, and a post-treatment observation. Patients first entered a 1-to 28-day screening period, and pre-treatment drugs were tapered to the doses that allowed them to be switched safely. Those patients experiencing a major depressive episode, which was defined as a total score of ≥18 on HAM-D17 at the end of the screening period, qualified for an 8-week, prospective treatment period. This period was designed to establish whether patients had an inadequate response to sertraline before being randomized to the ASC or the PSC group. During this period, all patients received single-blind sertraline 25-100 mg/day, at a dose of 25 mg/day for week 1, and between 25 and 100 mg/day from week 2 to week 6. For the 2 weeks from week 7 to week 8, they received sertraline 100 mg/day. When sertraline was administered at a dose of 25, 50, or 75 mg/day, the patients took 1, 2, or 3 tablets of PSC (sertraline 25 mg), respectively, and 1 tablet of PSC (sertraline 100 mg) when sertraline was administered at a dose of 100 mg/day. Patients who could not tolerate sertraline 100 mg/day were discontinued.
Patients meeting the criteria for inadequate response (<50% reduction in the HAM-D17 total score from baseline to the end of the prospective treatment period; a HAM-D17 total score of ≥14 at the end of the prospective treatment period; and a constant Clinical Global Impression -Improvement [CGI-I] score of ≥3 throughout the prospective treatment period) were eligible to enter a 6-week, randomized, double-blind treatment period (actual study visits, weeks [8] [9] [10] [11] [12] [13] [14] , in which participants were randomly assigned in a 1:1 ratio to receive either PSC or ASC. Investigators and patients were blinded by an allocation code of test drugs that was not disclosed until unblinding, after all the case report forms and the database were locked.
Four drug formulations of ASC and PSC tablets, A to D, were prepared. ASC tablets in formulation A to D contained 3, 6, 9, or 12 mg of aripiprazole and 100 mg of sertraline, whereas PSC tablets contained 100 mg of sertraline with the same appearance as the ASC formulations. The formulation A tablet was administered during week 1 and the dose was increased by once per week until week 4 if patients scored 4-7 on the CGI-I scale and tolerated the treatment. From week 5 to week 6, patients received a fixed formulation. Dose reduction for tolerability reasons was permitted, and the dose was decreased by one dose range per reduction.
Sertraline responders (patients who did not meet the criteria for inadequate response) continued sertraline administration using PSC (sertraline 100 mg) once daily for an additional 6 weeks in the treatment extension period. In the sertraline-tapering period, patients who proceeded to the double-blind treatment period were treated with reduced doses of sertraline (50 mg/day for 1 week and 25 mg/day for another week after the last treatment with the study drug) to terminate the treatment. In the posttreatment observation, all patients who proceeded to the double-blind treatment period visited the study center for post-treatment observation 3 weeks after the evaluation at week 6 (or discontinuation) after the start of the double-blind treatment period to undergo an investigation of treatment-emergent adverse events (TEAE) and a safety evaluation.
Assessments
The primary efficacy end-point was the mean change in the MADRS total score 16 from baseline (the end of the prospective treatment period [week 8]) to 6 weeks after the start of the double-blind treatment period (last observation carried forward [LOCF]). Other efficacy measures included the CGI-I score, mean changes in the CGI Severity of Illness (CGI-S) score, the HAM-D17 total score, and the self-rating version of the MADRS (MADRS-S) total score. 17 Mean changes in the Social Adaptation Self-Evaluation Scale (SASS) total score 18 and Apathy Scale (AS) total score 19 were assessed in patients who were able to understand Japanese or English. MADRS response and remission rates were also assessed. Response was defined as a reduction in the MADRS total score of at least 50% relative to the end of the prospective treatment period (baseline of the double-blind treatment period). Remission was defined as a response plus an absolute MADRS total score of ≤10. CGI-I improvement rate was defined as the proportion of patients with CGI-I scores of 1 or 2 at 6 weeks (LOCF).
The MADRS is the physician's rating of 10 depressive symptoms on a 7-point scale from 0 to 6. 16 The total score ranges from 0 to 60; higher scores indicate more severe depression. The SASS includes 21 questions, exploring patient motivation and behavior in the areas of work and leisure, familial and extrafamilial relationships, intellectual interest, satisfaction in roles, and patients' self-perception of their ability to manage and control their own environment. 18 Each answer is scored from 0 to 3, corresponding to minimal and maximal social adjustment, with a total score range of 0 to 60. The AS includes 14 questions exploring patient apathy. 19 Patients are provided with four possible answers: 'not at all,' 'slightly,' 'some,' or 'a lot.' Scores range from 0 to 42; higher scores indicate more severe apathy. The MADRS-S is the self-rating version of the MADRS. 17 It includes nine of the 10 MADRS items, rated on a 4-point Likert scale (from 0 to 3) with possible half-points ('apparent sadness,' based on clinician's observation, was excluded). The total score ranges from 0 to 27. Patients are instructed to rate symptom severity during the past 3 days; higher scores indicate more severe depression.
Safety was evaluated by monitoring TEAE, clinical laboratory tests, including serum prolactin, vital signs (blood pressure and pulse rate), 12-lead electrocardiograms, bodyweight, pregnancy tests, and the Columbia Suicide Severity Rating Scale. 20 In addition, evaluations of extrapyramidal symptoms included changes in scores for the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), 21 the Abnormal Involuntary Movement Scale (AIMS), 22 and the Barnes Akathisia Rating Scale (BARS). 23 
Statistical analyses
The efficacy dataset included all patients who were randomized to receive the study drug at least once in the double-blind treatment period, and for whom an MADRS total score was obtained at baseline and at least once after the start of the treatment. The safety dataset consisted of patients who were randomized to receive the study drug at least once in the double-blind treatment period, and for whom the safety evaluation data were obtained at least once after the start of the treatment. Analyses were performed using LOCF data.
The efficacy outcome measures, mean change in the MADRS, CGI-S, and HAM-D17 total scores from the end of the prospective treatment period to the end of the double-blind treatment period were assessed using an analysis of covariance (ANCOVA) model, with the score at the end of the prospective treatment period as a covariate and treatment groups and countries (Japan and other than Japan) as the factors. SASS total, AS total, and MADRS-S total scores were evaluated using ANCOVA with the score at the end of the prospective treatment period as a covariate and treatment groups as the factors. CGI-I scores at the end of the double-blind treatment period were assessed using ANCOVA with the CGI-S score at the end of the prospective treatment period as a covariate and treatment groups and countries as the factors. The least square (LS) means for each treatment group and the difference in the LS means between the ASC and the PSC groups and its twosided 95% confidence interval (CI) were calculated. MADRS response and remission rates and CGI-I improvement rates were compared between the ASC and the PSC groups using the Cochran-MantelHaenszel test with countries as strata. The common odds ratio (OR) between the ASC and PSC groups and its two-sided 95%CI were also calculated.
Sample size calculations were based on a predicted difference of 2.7 points (SD = 8.1) in the MADRS total score for the ASC group versus the PSC group. In each group, a sample size of 191 evaluable patients was projected to yield 90% power to detect treatment effects at a two-tailed alpha of 0.05. Therefore, the number of randomized patients was set at a total of 400 (200 in the ASC group and 200 in the PSC group), considering the potential number of patients excluded from the analysis. The planned number of patients enrolled in the prospective treatment period was 800 because in the four previous studies, approximately 50% of the patients who had been enrolled in the selective serotonin reuptake inhibitor/serotonin-noradrenaline reuptake inhibitor treatment period subsequently proceeded to the double-blind period.
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RESULTS
Patient disposition
In total, 1222 patients were screened, of whom 899 were eligible to enter the prospective treatment period; 735 patients completed this phase. Of these, 323 patients met the criteria for response during prospective treatment and did not proceed to the double-blind treatment period. Of 412 patients randomized in the double-blind treatment period, 203 patients received PSC and 209 patients received ASC. All patients who received PSC were included in the efficacy and safety datasets. All patients who received ASC were included in the safety dataset (n = 209), and all patients who received ASC except one patient without efficacy data were included in the efficacy dataset (n = 208). More than 90% (90.1% and 92.8% in the PSC and the ASC groups, respectively) of patients completed the double-blind period (Fig. 1) . Reasons for treatment discontinuation are provided in Figure 1 .
Treatment groups of randomized patients were well balanced with respect to baseline demographics and clinical characteristics ( Table 1) . Most patients were enrolled in Japan: 70.0% in the PSC group and 75.5% in the ASC group.
The mean (AESD) dose of aripiprazole administered as ASC (n = 209) at the end-point of the doubleblind treatment period was 6.3 (AE3.5) mg/day. The distribution of aripiprazole administered as ASC at the end-point was as follows: 3 mg/day, 44.5%; 6 mg/day, 18.7%; 9 mg/day, 19.1%; and 12 mg/day, 17.7%. For patients in the PSC group (n = 203), the mean dose equivalent (based on the formulation of tablets) at the end-point was 7.8 (AE3.7) mg/day. The distribution of the equivalent dose at the end-point was as follows: 3 mg/day, 27.1%; 6 mg/day, 22.7%; 9 mg/day, 11.8%; and 12 mg/day, 38.4%. Table 2 provides the LOCF mean change from baseline to the end-point for the MADRS total score, CGI-S, HAM-D17 total score, SASS total score, AS total score, and MADRS-S total score. Patients in the ASC group experienced significantly greater improvement in the mean MADRS total score at the end-point than patients in the PSC group. The difference in reduction of the MADRS total score between treatment groups was already apparent by week 1 of double-blind treatment, and the ASC group continued to show improvements throughout the study (Fig. 2) . The MADRS response rate at week 6 was significantly higher in the ASC group (37.5%) than in the PSC group (25.6%; Fig. 3a) . The common OR between the treatment groups (ASC/PSC) was 1.73 (95%CI, 1.14-2.65; P = 0.0106). The MADRS remission rate was also significantly higher in the ASC group (29.3%) than in the PSC group (20.2%) at week 6 (Fig. 3b) . The common OR between the treatment groups (ASC/PSC) was 1.65 (95%CI, 1.05-2.61; P = 0.0307). ASC produced significantly greater improvements in CGI-S, HAM-D17 total score, SASS total score, AS total score, and MADRS-S total score than PSC ( Table 2 ). The end-point CGI-I score (mean AE standard error [SE]) showed a significantly greater All patients who received placebo/sertraline combination were included in the efficacy and safety datasets. All patients who received aripiprazole/sertraline combination were included in the safety dataset (n = 209), and all patients who received aripiprazole/sertraline combination except one patient without efficacy data were included in the efficacy dataset (n = 208). improvement with ASC (2.6 AE 0.1) than with PSC (2.9 AE 0.1, P = 0.0042). The CGI-I improvement rate at week 6 was significantly higher in the ASC group (46.2%) than in the PSC group (34.5%). The common OR between the treatment groups (ASC/PSC) was 1.62 (95%CI, 1.09-2.42; P = 0.0167).
Efficacy
Safety
During the double-blind treatment period, 128 (61.2%) patients in the ASC group and 108 (53.2%) patients in the PSC group experienced at least one TEAE (Table 3) . Among the TEAE occurring with an incidence of ≥5% in the ASC group, akathisia was the only one that occurred at ≥2 times that of the PSC group. The majority of TEAE were mild or moderate in severity. No serious or severe TEAE occurred in the ASC group; two serious TEAE were reported in two patients in the PSC group (clavicle fracture and gastric ulcer). No deaths were reported in the study. Discontinuation due to TEAE in the double-blind treatment period occurred in four patients in the ASC group and in three patients in the PSC group. Extrapyramidal symptom-related TEAE led to discontinuation in one patient from each treatment group. TEAE leading to dose reduction were reported in 10 (4.8%) patients in the ASC group and seven (3.4%) patients in the PSC group.
The mean changes from baseline in the DIEPSS, AIMS, and BARS scores were small at any time-point Data are expressed as n (%) except where specified otherwise. †
Mean (SD).
All patients who received aripiprazole/sertraline combination except one patient without efficacy data were included in the efficacy dataset (n = 208). MADRS, Montgomery-Åsberg Depression Rating Scale.
© 2018 The Author Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology after the start of the double-blind treatment period, and most patients had no symptoms (i.e., value = 0 at all time-points) on the DIEPSS, AIMS, and BARS scores in both groups. The LS mean (AESE) weight change during the double-blind treatment period was significantly greater in the ASC group (1.87 AE 0.13 kg) than in the PSC group (0.28 AE 0.13 kg, P < 0.0001; LOCF). A statistically significant difference was also noted in the proportion of patients who showed a ≥7% weight gain from the double-blind baseline (LOCF; ASC, 9.7%; PSC, 1.5%, P = 0.0003). The LS mean (AESE) body mass index change during the double-blind treatment period was significantly greater in the ASC group (0.66 AE 0.05) than in the PSC group (0.10 AE 0.05, P < 0.0001; LOCF). There were no clinically meaningful differences between the ASC group and the PSC group in laboratory values, vital signs, or electrocardiogram. The mean (AESD) serum prolactin concentrations decreased in the ASC group (−3.650 AE 6.611 μg/ L) compared with the PSC group (−0.302 AE 5.186 μg/ L) during the double-blind treatment period (LOCF). The mean serum prolactin concentrations at 6 weeks after the start of the double-blind period were within the normal range in both groups.
The results of the Columbia Suicide Severity Rating Scale assessments indicated that the percentages of patients with suicidal ideations or behaviors were lower in the ASC group than in the PSC group at any time-point after the start of the double-blind period. No patients had new serious suicidal ideations or new suicidal behaviors in the ASC group, and one new serious suicidal ideation and one new suicidal behavior were reported in the PSC group after the start of the double-blind period.
DISCUSSION
This study showed that ASC was more effective than PSC for the improvement of depressive symptoms and was well tolerated in patients with MDD who had responded inadequately to sertraline monotherapy. In this study, onset of the antidepressant action was found at an early stage of the double-blind treatment period, and meaningful improvement continued thereafter. These findings are similar to those of previous placebocontrolled studies of aripiprazole as augmentation to ADT conducted in the USA and Japan. [8] [9] [10] [11] ASC was associated with significantly higher MADRS response and remission rates than PSC at the All patients who received aripiprazole/sertraline combination except one patient without efficacy data were included in the efficacy dataset (n = 208). ANCOVA, analysis of covariance; AS, Apathy Scale; CGI-S, Clinical Global Impression -Severity of Illness; CI, confidence interval; HAM-D17, 17-item Hamilton Depression Rating Scale; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Depression Rating Scale; MADRS-S, Montgomery-Åsberg Depression Rating Scale -Self-rating; SASS, Social Adaptation Self-Evaluation Scale; SE, standard error. study end-point. The results of this trial are similar to those of the previous placebo-controlled studies of aripiprazole as adjunctive therapy to ADT. [8] [9] [10] [11] ASC was significantly more effective than PSC for the improvement of disability in apathy and social functioning, as measured using the AS and SASS, respectively. The persistence of apathy in a patient treated for depression can have a negative impact on cognitive and physical functioning. 24 Social dysfunction and disability are also important consequences of a depressive episode. Social function or social adjustment refers to the function of an individual within his or her usual environment and is manifested in performance and interactions occurring in a All patients who received ASC except one patient without efficacy data were included in the efficacy dataset (n = 208). Response was defined as ≥50% decrease in MADRS total score from end of the prospective treatment period. Remission was defined as MADRS total score of ≤10 and ≥50% decrease in MADRS total score from end of the prospective treatment period. *P < 0.05; **P < 0.01; ***P < 0.001 vs PSC (Cochran-Mantel-Haenszel test). 
